Shanghai Junshi Biosciences Co., Ltd. (HKG:1877)
15.94
+0.22 (1.40%)
Nov 10, 2026, 4:08 PM HKT
Shanghai Junshi Biosciences Employees
Shanghai Junshi Biosciences had 3,055 employees as of June 30, 2026. The number of employees increased by 152 or 5.24% since the number was reported on December 31, 2025. That makes Shanghai Junshi Biosciences the 7,852nd largest employer in the world and 602nd in Hong Kong.
Employees
3,055
Change
152
Growth
5.24%
Revenue / Employee
1.29M HKD
Profits / Employee
-172.74K HKD
Market Cap
32.38B
Employees Chart
| Date | Employees | Change | Growth | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Jun 30, 2026 | 3,055 | 152 | 5.24% | 3,055 | 0 |
| Dec 31, 2025 | 2,903 | 325 | 12.61% | 2,903 | 0 |
| Dec 31, 2024 | 2,578 | 10 | 0.39% | 2,578 | 0 |
| Dec 31, 2023 | 2,568 | -393 | -13.27% | 2,568 | 0 |
| Dec 31, 2022 | 2,961 | 156 | 5.56% | 2,961 | 0 |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Genscript Biotech | 6,135 |
| 3SBio | 6,068 |
| Shanghai Henlius Biotech | 4,082 |
| Akeso | 4,082 |
| RemeGen | 3,145 |
| Biocytogen Pharmaceuticals (Beijing) | 1,922 |
| Zai Lab | 1,784 |
| Keymed Biosciences | 1,768 |
Shanghai Junshi Biosciences News
- 11 days ago - Shanghai Junshi Biosciences Earnings release: Q3 2026 - Filings
- 11 days ago - Shanghai Junshi Biosciences Slides: Q3 2026 - Filings
- 12 days ago - Junshi's Toripalimab Subcutaneous Injection Application Accepted In China For Bladder Cancer - Nasdaq
- 12 days ago - Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application of Toripalimab (Subsutaneous Injection) for the 1st-Line Treatment of HER2-Expressing Urothelial Carcinoma - Financial Post
- 12 days ago - Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application of Toripalimab (Subsutaneous Injection) for the 1st-Line Treatment of HER2-Expressing Urothelial Carcinoma - GlobeNewsWire
- 17 days ago - Junshi Biosciences Announces Completion of First Patient Dosing in the Phase 3 Clinical Trial of JS203 in Combination with Chemotherapy for the Treatment of Diffuse Large B-cell Lymphoma - Financial Post
- 17 days ago - Junshi Biosciences Announces Completion of First Patient Dosing in the Phase 3 Clinical Trial of JS203 in Combination with Chemotherapy for the Treatment of Diffuse Large B-cell Lymphoma - GlobeNewsWire
- 2 months ago - Shanghai Junshi Biosciences Earnings release: H1 2026 - Filings